1. Home
  2. NCRA vs AYTU Comparison

NCRA vs AYTU Comparison

Compare NCRA & AYTU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nocera Inc.

NCRA

Nocera Inc.

N/A

Current Price

$0.84

Market Cap

12.3M

ML Signal

N/A

Logo Aytu BioPharma Inc.

AYTU

Aytu BioPharma Inc.

HOLD

Current Price

$2.90

Market Cap

23.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NCRA
AYTU
Founded
2002
N/A
Country
Taiwan
United States
Employees
22
N/A
Industry
Farming/Seeds/Milling
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
12.3M
23.4M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
NCRA
AYTU
Price
$0.84
$2.90
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$9.33
AVG Volume (30 Days)
80.1K
110.9K
Earning Date
04-01-2026
02-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$14,106,275.00
$63,696,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$47.32
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.72
$0.95
52 Week High
$2.40
$2.82

Technical Indicators

Market Signals
Indicator
NCRA
AYTU
Relative Strength Index (RSI) 41.75 74.77
Support Level $0.78 $2.42
Resistance Level $0.93 $2.59
Average True Range (ATR) 0.12 0.17
MACD 0.01 0.03
Stochastic Oscillator 20.43 81.21

Price Performance

Historical Comparison
NCRA
AYTU

About NCRA Nocera Inc.

Nocera Inc is engaged in the manufacturing of aquaculture equipment, construction of aquaculture facilities, managing and operating aquaculture facilities, and consulting for third-party operators of aquaculture facilities. Its primary business operations consist of the design, development, and production of RASs large-scale fish tank systems, for fish farms along with consulting, technology transfer, and aquaculture project management services to new and existing aquaculture management business services.

About AYTU Aytu BioPharma Inc.

Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.

Share on Social Networks: